Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

1 Jan 2018

Abstract excerpt

Genetic and/or epigenetic changes provide antigen-derived diversity in neoplastic cells. Beside, these cells do not initiate immune response of host organisms. A variety of factors are responsible for the resistant to treatment, including individual variations in patients and somatic cell genetic differences in tumors, even those from the same tissue of origin. Immune system is controlled by several controlling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29850620
DOI: 10.1155/2018/1982423

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune Checkpoint Inhibitors to Treat Malignant LymphomasPMID 29850620Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Immune checkpoints and cancer in the immunogenomics eraSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious DiseasesSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Case-Illustrated Narrative ReviewSemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read ↗

Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, other than Abscopal Effect: A Systematic ReviewSemantic proximity Read ↗

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read ↗

Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.